Sulfonylureas as second line treatment for type 2 diabetes

BMJ. 2018 Jul 18:362:k3041. doi: 10.1136/bmj.k3041.

Authors

Lucy D'Agostino McGowan¹, Christianne L Roumie²

Affiliations

¹ Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
² Veterans Health Administration-Tennessee Valley Healthcare System Geriatric Research Education Clinical Center (GRECC), and Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA christianne.roumie@vanderbilt.edu.

PMID: 30021790
DOI: 10.1136/bmj.k3041

No abstract available

Publication types

Editorial
Comment

MeSH terms

Cohort Studies
Diabetes Mellitus, Type 2*
Humans
Hypoglycemic Agents
Sulfonylurea Compounds

Substances

Hypoglycemic Agents
Sulfonylurea Compounds

Grants and funding